Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

127 Results

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Status: Current

Mar 2025

Regimen

VORA

Cancer Type:

Central Nervous System

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative, Palliative

Drugs Used:

vorasidenib (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

Guidelines and Advice

Safe Handling of Hazardous Drugs

Status: Current
ID: GL 16-3
Version: 3

Mar 2022

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Aug 2022

Pages